Institution: | 1.CRMBM UMR AMU CNRS 7339,Aix-Marseille Université,Marseille,France;2.AP-HM, CHU Timone, P?le d’Imagerie,CEMEREM,Marseille,France;3.AP-HM, CHU Timone, P?le de Neurosciences Cliniques, Service de Neurophysiologie,Marseille,France;4.AP-HM, CHU Timone, CIC CPCET, Service de Pharmacologie Clinique et Pharmacovigilance,Marseille,France;5.Inserm, UMR_S 1106, INS, Institut de Neurosciences des Systèmes,Aix-Marseille Université,Marseille,France;6.UMR 825 Inserm, Imagerie Cérébrale et Handicaps Neurologiques,Université Toulouse III Paul Sabatier,Toulouse,France;7.Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine,University of Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Barcelona,Spain;8.U1171 Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders,University of Lille,Lille,France;9.Neurosciences Therapeutic Area Unit,GlaxoSmithKline R&D,Stevenage,UK;10.Department of Physiology and Pharmacology,University of Rome “Sapienza”,Rome,Italy;11.Institute of Neurology,Catholic University of The Sacred Heart,Rome,Italy |